# A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

> **NCT02759250** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 11 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** ARGX-110

## Key facts

- **NCT ID:** NCT02759250
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02759250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02759250, "A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02759250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*